The Oculyze BB 2.0 yeast monitoring system is debuting via BIOTECON Diagnostics

We’ve been writing about the Oculyze Better Brewing system for a few years now. It is a mobile app that allows you to automatically determine yeast concentration, viability and budding count in a matter of minutes. The data management system puts yeast analysis in the cloud and allows you to review your results history from anywhere, anytime. And it looks like an updated version is now available.

BIOTECON Diagnostics, a renowned food and beverage quality testing provider, just signed a deal to become the exclusive global distributor of Oculyze’s latest technological innovation the Oculyze Better Brewing (BB) 2.0.

The Oculyze BB 2.0 hardware/software combination, enables breweries to determine viability and concentration of their yeast in less than a minute. It is compact, weighing under 200 g and can easily fit within the palm of a brewer’s hand. The technology comes equipped with a high-quality optical scope that is comparable to a high end laboratory microscope and is compatible with most android mobile phones and tablets.

Halloween beer fun: We rank the brewer’s yeasts that are most likely haunted.

“I am delighted to announce this strategic partnership with BIOTECON Diagnostics as we look to rapidly build and consolidate the Oculyze BB 2.0 market share and brand value across the world,” stated Kilian Moser, cofounder and chief executive officer of Oculyze. “As a relatively young and innovative biotech firm, we believe in focusing on our core strengths to continuously create and roll out key technological solutions that are smart, easy to use and cost efficient.”

“BIOTECON Diagnostics is proud of the long-standing relationships that have been built up over the years with various partners, also in the brewing sector, and we continue to focus on expanding our product portfolio,” stated Alois Schneiderbauer, chief business officer of BIOTECON Diagnostics. “We are, therefore, pleased to have the confidence to add the Oculyze BB 2.0 to our global portfolio as we also believe in the technology and advantage of the product and have many common interests with Oculyze.”